Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03463616
Other study ID # MRvsCT
Secondary ID
Status Completed
Phase
First received
Last updated
Start date March 15, 2018
Est. completion date December 31, 2020

Study information

Verified date April 2021
Source Sahlgrenska University Hospital, Sweden
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Rectal cancer is a common diagnosis. The prognosis after treatment has improved over the last decades, partly due to neoadjuvant radio(chemo)therapy, but also due to improved surgical technique (TME) and, in certain cases, due to adjuvant therapy after surgery. For some 15-20 years, treatment of metastasis has changed; liver- and lung metastasis in certain situations are surgically removed, or in the liver, treated with ablation (radio-frequency). During the same period the possibilities for chemotherapy of metastatic disease have improved, with new drugs and more drug regimens. These changes in treatment pathways have required changes in how patients with newly diagnosed rectal cancer are "worked up" pre-treatment. Starting in the early 2000s magnetic resonance imaging of the pelvic area has developed and is today mandatory to be able to adequately stage the tumour and plan for the multi-modal treatment before and after surgery. In many hospitals the set-up is a combination of computed tomography of the abdomen and chest and to this a MRI of the pelvic organs is added, whereas others have adopted MRI also for the abdominal part, thus having an MRI of the liver for the diagnosis of liver metastasis initially, before surgery. For the chest organs, CT is still normative. MRI has a higher sensitivity and specificity to detect liver metastasis, compared with CT. In order to plan the liver surgery/ablations, most liver surgeons rely on MRI for detailed information about the position of the metastasis and the relation to large vessels. The aim of this study is to examine the possible differences in percentage of patients requiring further radiology examinations after basic set-up comparing the routine of initial MRI of abdomen (and pelvic organs) with the routine of initial CT of the abdomen (and MRI of the pelvic organs). Further included is an analysis of the rate of liver metastasis using the two different routines, and finally outcome over 12 months in terms of liver treatment for metastasis.


Description:

Background: Rectal cancer is a common diagnosis in both men and women, more commonly occurring in men (60%) than women (40%). In Sweden some 2000 cases are diagnosed each year. The prognosis after treatment has improved over the last decades, partly due to neoadjuvant radio(chemo)therapy, but also due to improved surgical technique (TME) and, in certain cases, due to adjuvant therapy after surgery. For some 15-20 years, treatment of metastasis has changed; liver- and lung metastasis in certain situations are surgically removed, or in the liver, treated with ablation (radio frequency). During the same period the possibilities for chemotherapy of metastatic disease have improved, with new drugs and more drug regimens. These changes in treatment pathways have required changes in how patients with newly diagnosed rectal cancer are "worked up" pre-treatment. Starting in the early 2000s magnetic resonance imaging of the pelvic area has developed and is today mandatory to be able to adequately stage the tumour and plan for the multi-modal treatment before and after surgery. In many hospitals the set-up is a combination of computed tomography of the abdomen and chest and to this a MRI of the pelvic organs is added, whereas others have adopted MRI also for the abdominal part, thus having an MRI of the liver for the diagnosis of liver metastasis initially, before surgery. For the chest organs, CT is still normative. MRI has a higher sensitivity and specificity to detect liver metastasis, compared with CT. In order to plan the liver surgery/ablations, most liver surgeons rely on MRI for detailed information about the position of the metastasis and the relation to large vessels. The objective of the study is to examine: The possible differences in percentage of patients requiring further radiology examinations after basic set-up comparing the routine of initial MRI of abdomen (and pelvic organs) with the routine of initial CT of the abdomen (and MRI of the pelvic organs). Further included is an analysis of the rate of liver metastasis using the two different routines, and finally outcome over 12 months in terms of liver treatment for metastasis. Hypothesis: Primary: • Patients who underwent initial abdominal MRI had a significantly lower need for additional radiology examinations compared with those who underwent initial CT abdomen. Secondary: - A higher proportion of patients who underwent initial abdominal MRI underwent liver treatment aiming for cure at 12 months. - Abdominal MRI as initial examination resulted in a higher proportion of detected liver metastasis. - Cost effectiveness analysis will show that initial abdominal MRI of the abdominal organs is cost-effective. Design: A retrospective study using clinical details such as date for diagnosis, clinical tumour stage, type of surgical treatment and date, pathology tumour stage, local recurrence and survival at 36 months from the Swedish ColoRectal Cancer Registry for patients with rectal cancer treated at Sahlgrenska University Hospital and Norra Älvsborg Hospital during the years collecting patients backwards from 2015-12-31 until sufficient number is reached (see below "Sample size"). Data will be collected in the radiology patient documentation at the two hospitals using the original radiology report for the index examinations as well as type and number of additional radiology examinations and the reports for those. For patients with liver metastases in the original radiology report at the index work-up and in cases with indeterminate initial results, the original radiology examinations will be re-evaluated by one or if possible two radiologists. Data from the clinical patient records on treatment plan (index treatment) and time and type of treatment for liver metastasis. No direct contact with patients is planned, and only data already collected (see above) will be used. Methodology: Through Regional Cancer Center West (RCC Väst) appropriate data from to Swedish ColoRectal Cancer Register will be collected, consisting of age, time for diagnosis, time for multidisciplinary conference, time for oncological treatment, time for surgery, cTNM as well as pTNM, performed treatment/s within 12 months, recurrence/s and survival (3 years). Data to be collected from radiology reports include presence of liver metastasis, number of liver metastasis, additional radiology examinations after index work-up - type and number as well as findings of liver metastasis. Additional findings of distant metastases to retro peritoneal lymph-nodes and to peritoneum will also be recorded. Data from re-evaluation of examinations for all patients diagnosed with liver metastases such as number of metastases, number of small metastases (<10mm), metastases to retro peritoneal lymph-nodes and to peritoneum. Data to be collected from hospital records for all patients include time line for different aspects of treatment including multidisciplinary conference (and decision), oncological treatment and liver surgery until 12 months from diagnosis.


Recruitment information / eligibility

Status Completed
Enrollment 320
Est. completion date December 31, 2020
Est. primary completion date March 31, 2020
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - All patients in the Swedish Colo- Rectal Cancer Registry (SCRCR) and treated for rectal cancer at Sahlgrenska University Hospital and Norra Älvsborg Hospital 2013-2015. Exclusion Criteria: - None

Study Design


Intervention

Radiation:
CT abdomen
CT scan of abdomen for metastasis staging of rectal cancer
MRI abdomen
MRI of abdomen for metastasis staging of rectal cancer

Locations

Country Name City State
Sweden Sahlgrenska university hospital Gothenburg

Sponsors (1)

Lead Sponsor Collaborator
Sahlgrenska University Hospital, Sweden

Country where clinical trial is conducted

Sweden, 

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage of patients who needed additional radiology examination/s before treatment planning after routine MRI of abdominal organs compared with routine CT of abdominal organs. 3 months
Secondary Comparison of percentage of patients treated with liver surgery/ablation within 12 months between the two groups. 12 months
Secondary Comparison of the percentage of patients who were diagnosed with liver metastasis, between the two groups. 3 years
Secondary Cost effectiveness analysis of routine MRI of abdominal organs compared with routine CT of abdominal organs. Total cost differences between MRI and CT-scan as primary routine work-up measured in USD. 3 years
Secondary Overall survival after 3 years 3 years
Secondary Disease free survival after 3 years 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT06380101 - Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC) N/A
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Recruiting NCT04323722 - Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT04088955 - A Digimed Oncology PharmacoTherapy Registry
Active, not recruiting NCT01347697 - Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer N/A
Recruiting NCT04495088 - Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer Phase 3
Withdrawn NCT03007771 - Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia Phase 1
Terminated NCT01347645 - Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer Phase 1/Phase 2
Not yet recruiting NCT03520088 - PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS N/A
Recruiting NCT05556473 - F-Tryptophan PET/CT in Human Cancers Phase 1
Recruiting NCT04749381 - The Role of TCM on ERAS of Rectal Cancer Patients Phase 2
Enrolling by invitation NCT05028192 - Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
Recruiting NCT03283540 - Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
Completed NCT04534309 - Behavioral Weight Loss Program for Cancer Survivors in Maryland N/A
Recruiting NCT05914766 - An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer N/A
Recruiting NCT04852653 - A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
Recruiting NCT03190941 - Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients Phase 1/Phase 2
Completed NCT02810652 - Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection N/A
Terminated NCT02933944 - Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer Phase 1